Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 05, 2018 07:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Announces New OCA Data to be Presented at The Liver Meeting® 2018

NEW YORK, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
October 31, 2018 07:05 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

Worldwide Ocaliva net sales of $46.6 million in the third quarter of 2018Leading Phase 3 NASH program continues to advance: REGENERATE trial in NASH patients with advanced liver fibrosis expected to...
October 24, 2018 16:05 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Announce Third Quarter 2018 Financial Results on October 31, 2018

NEW YORK, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
September 26, 2018 07:05 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Present at Upcoming Investor Conference

NEW YORK, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
August 29, 2018 07:05 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Present at Upcoming Investor Conferences

NEW YORK, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
August 02, 2018 07:05 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update

Worldwide Ocaliva net sales of $43.2 million in the second quarter of 2018Leading Phase 3 NASH program continues to advance: REGENERATE trial in NASH patients with advanced liver fibrosis expected to...
July 26, 2018 16:05 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Announce Second Quarter 2018 Financial Results on August 2, 2018 and Present at Upcoming Investor Conference

NEW YORK, July 26, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
June 07, 2018 17:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Present at Upcoming Conference

NEW YORK, June 07, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
May 08, 2018 07:05 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Announces First Quarter 2018 Financial Results, Issues 2018 Ocaliva Net Sales Guidance and Provides Business Update

Worldwide Ocaliva net sales of $35.2 million in the first quarter of 20182018 worldwide Ocaliva net sales currently expected to be between $170 million and $185 millionContinuing to advance leading...
May 01, 2018 17:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Announce First Quarter 2018 Financial Results on May 8, 2018 and Present at Upcoming Investor Conferences

NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...